Differentially methylated DNA regions in early childhood wheezing: an epigenome-wide study using saliva

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/1690516 since 2020-04-05T10:23:38Z

Published version:
DOI:10.1111/pai.13023

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
Differentially methylated DNA regions in early childhood wheezing: an epigenome-wide study using saliva

Maja Popovic1, Valentina Fiano1, Francesca Fasanelli1, Morena Trevisan1, Chiara Grassoi1, Manuela Bianca Assumma2, Anna Gillio-Tosi1, Silvia Polidoro2, Laura De Marco1, Franca Rusconi1, Franco Merletti1, Daniela Zugna1, Lorenzo Richiardi1

Affiliations
1 Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin; Centro di Ricerca in Medicina Sperimentale (CeRMS) and CPO Piemonte, Turin, Italy
2 Italian Institute for Genomic Medicine (IIGM), Turin, Italy.
3 Unit of Epidemiology, ‘Anna Meyer’ Children’s University Hospital, Florence, Italy

Running title: Epigenome-wide study of infant wheezing

Corresponding author:
Maja Popovic
Department of Medical Sciences,
University of Turin
Via Santena 7
10126 Turin, Italy
E-mail: maja.popovic@unito.it
Phone: +39(0) 116334628

Conflicts of interest
The authors have no potential conflicts of interest to disclose.

Financial support
The NINFEA study was partially funded by the Compagnia San Paolo Foundation. This research received funding specifically dedicated to the Department of Medical Sciences from Italian Ministry for Education, University and Research (Ministero dell'Istruzione, dell'Università e della Ricerca - MIUR) under the programme "Dipartimenti di Eccellenza 2018 – 2022". M.P. was supported by the European Commission through the Erasmus Mundus for Western Balkans II programme. L.R. received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 733206, LIFE-CYCLE project.

Abstract
Background Epigenetics may play a role in wheezing and asthma development. We aimed to examine infant saliva DNA methylation in association with early childhood wheezing.

Methods A case-control study was nested within the NINFEA birth cohort with 68 cases matched to 68 controls by sex, age (between 6 and 18 months, median: 10.3 months) and season at saliva sampling. Using a bump hunting region-based approach we examined associations between saliva methylome measured using Illumina Infinium HumanMethylation450k array and wheezing between 6 and 18 months of age. We tested our main findings in independent publicly available datasets of childhood respiratory allergy and atopic asthma, with DNA methylation measured in different tissues and at different ages.

Results We identified one wheezing-associated differentially methylated region (DMR) spanning ten sequential CpG sites in the promoter-regulatory region of PM20D1 gene (family wise error rate <0.05). The observed associations were enhanced in children born to atopic mothers. In the publicly available datasets, hypermethylation in the same region of PM20D1 was consistently found at different ages and in all analysed tissues (cord blood, blood, saliva and nasal epithelia) of children with respiratory allergy/atopic asthma compared with controls.

Conclusion This study suggests that PM20D1 hypermethylation is associated with early childhood wheezing. Directionally consistent epigenetic alteration observed in cord blood and other tissues at older ages in children
with respiratory allergy and atopic asthma provides suggestive evidence that a long-term epigenetic modification, likely operating from birth, may be involved in childhood atopic phenotypes.

**Key words:** wheezing, asthma, children, epigenome-wide association study, saliva, epigenetics, infant, EWAS, DMR, PM20D1

**Introduction**

Over the past 20 years the concept of developmental origins of health and disease has become widely accepted and expanded to many complex conditions, including, but not limited to, immunometabolic disorders, such as obesity, asthma, and cardiovascular diseases. This theory states that intrauterine and early postnatal exposures can induce biological changes that influence later disease susceptibility. Alteration of the epigenome is one potential mechanism by which environmental exposures may cause structural and/or functional changes in cells, tissues, and organs of developing individuals. Several in utero exposures, such as maternal smoking, maternal body mass index (BMI), and exposure to air pollution have been associated with alterations in infant DNA methylation, most often measured in cord blood. Most of these exposures are also known to be associated with childhood wheezing and asthma. In addition, postnatal environment, such as air pollution, early microbial exposures, and child’s growth, may increase the risk of childhood wheezing disorders and asthma through epigenetic modifications.

Although DNA methylation is the most studied epigenetic mechanism to date, post-translational histone modifications have also been implicated in the T-cells differentiation and airway remodelling, contributing to the epigenetic regulation of allergic phenotypes, including asthma.

While asthma is a diagnostic category typically used from school age onwards, the disease often initiates much earlier, with wheezing episodes starting from early infancy. Wheezing in early childhood, especially if accompanied with allergic sensitization or other atopic conditions, has been shown to be a strong predictor of asthma development and later lung function, and thus is often studied in the context of large epidemiological studies.

Several previous studies reported associations with childhood wheezing and asthma of DNA methylation changes at a number of single methylation sites and differentially methylated regions (DMRs). A large cross-sectional EWAS of childhood asthma conducted within the MeDALL consortium identified an altered peripheral blood DNA methylation at 35 CpG sites; most of the associations were with school age asthma, while only one CpG site was associated with asthma at preschool age. Importantly, all the associations were largely attenuated, but persisted, following adjustment for eosinophil count. In the same study, DNA methylation patterns at 14 out of the 35 identified CpG sites were replicated in peripheral blood of children with asthma from independent cohorts, while none of the identified CpG sites was associated with asthma when DNA methylation was measured in cord blood at birth. A recent meta-analysis of epigenome-wide DNA methylation and school-age asthma identified 9 CpG sites and 35 DMRs in cord blood associated with childhood asthma. These early DNA methylation markers were, however, not among much larger number of hits identified in a cross-sectional analysis within the same study where both asthma and blood DNA methylation were assessed in school-age children and adolescents.

It is well established that DNA methylation is tissue-specific, and for diseases for which the local effect might be more pronounced than their systemic effect, such as asthma, the tissue selection for DNA methylation measurement is essential. Bronchial tissue is difficult to obtain in population studies, and most of the studies assessing epigenetic markers of wheezing and asthma focused on DNA methylation measured in blood samples. Some studies, however, found asthma methylationic markers in buccal, nasal and airway epithelial cells. As saliva is a candidate body fluid reflecting pathological changes in the airways during asthma development, we aimed at investigating the associations between infant saliva methylome and early childhood wheezing within the Italian birth cohort study NINFEA.

**Methods**

**Study population**

The NINFEA (Nascita ed INFanzia: gli Effetti dell’Ambiente) study is an Italian web-based birth cohort that recruited approximately 7500 pregnant women during the period 2005-2016 (https://www.progettoninfea.it). Members of the cohort are children of mothers who had access to the Internet, enough knowledge of Italian to...
complete online questionnaires, and volunteered to participate at any time during the pregnancy. At enrolment women completed the baseline questionnaire, and children are then followed up with five questionnaires completed by mothers 6 and 18 months after delivery, and when children turn 4, 7 and 10 years of age. At the end of the 6-month questionnaire mothers were invited to donate their and their child’s saliva samples using the Oragene™ DNA self-collection kits (OG-250, DNA Genotek, Inc., Ottawa, Ontario, Canada). Mothers who did not respond to this initial invitation were invited again at the end of the 18-month and 4-year questionnaire. The samples are stored in a biobank at -80°C. Additional information on recruitment, study advertisement and follow-up is available in the dedicated paper.27

We conducted a nested case-control study within the subset of the NINFEA children who met the following criteria: i) singleton child, ii) saliva sample collected between 6 and 18 months after birth (time window for the outcome assessment), iii) residence in the Province of Turin, and iv) born to mother who did not have asthma active during the index pregnancy.

Wheezing was assessed from the questionnaire completed 18 months after delivery using the standardized question from the International Study on Asthma and Allergies in Childhood (ISAAC), and was defined as at least one episode of wheezing or whistling in the chest occurred between 6 and 18 months of age. At the time of sampling of cases and controls (database version 02.2014), there were 551 children meeting the aforementioned inclusion criteria, of whom 79 had at least one wheezing episode between 6 and 18 months of age. Of the 79 children with wheezing, seven samples with the lowest DNA content were excluded, and the remaining 72 cases were matched to controls by sex, season and age at saliva donation keeping a constant 1:1 ratio.

The NINFEA study protocol and subsequent amendments have been approved by the Ethical Committee of the San Giovanni Battista Hospital—CTO/CRF/Maria Adelaide Hospital, Turin, Italy (approval N.0048362). All women gave their informed consent at recruitment and when donating saliva samples.

DNA methylation data
The methylation status of over 485,000 probes was measured using the Illumina Infinium HumanMethylation450 BeadChip (Illumina, Inc., San Diego, CA). Details on pre-processing of samples and data quality control can be found in the Supporting Information file (Methods, DNA methylation measurement, data pre-processing, and quality control). DNA methylation for each probe was expressed as beta value (ratio of methylated probe intensity to overall intensity, representing 0 to 100% methylation at each probe). After quality control and probes filtering 136 samples with DNA methylation measured in 421,782 probes remained for the analyses.

Statistical analyses
To remove variance caused by batch and unmeasured technical effects, and to account for cell-type heterogeneity we performed surrogate variable analysis using the R package sva.28,29

We conducted an exploratory epigenome-wide single-probe analysis using logistic regression models adjusted for matching variables (child's sex, age and season at saliva sampling) and for presence of siblings at birth, maternal age at delivery, maternal smoking after delivery as a proxy for child’s exposure to passive smoking and day-care attendance between 6 and 18 months of age. Bonferroni-corrected and Benjamini and Hochberg False-Discovery Rate (FDR)-corrected p-values were calculated to account for multiple testing.

Differentially methylated regions associated with early childhood wheezing were analysed using the R package bumphunter.30 We clustered probes with a maximum distance of 1kb, and then with a bumphunter function fitted a linear model for each site with wheezing as the independent variable, adjusting for the aforementioned confounding and matching variables used in the exploratory epigenome-wide association analyses. The estimated coefficients of the case-control status were then smoothed within the clusters using running medians. We performed 1000 random bootstrap iterations to estimate an empirical null distribution. The regions of interest were chosen based on the cut-off threshold of 5% in the methylation beta value difference between cases and controls, retaining only regions with at least three probes within the region and with family-wise error rate (FWER) <0.05.

We further tested whether some of in utero exposures confounded the observed associations by performing additional adjustments for maternal history of atopy (atopic dermatitis and/or allergic rhinitis; note that mothers with history of asthma were a priori excluded from the study), maternal depression and/or anxiety and maternal
genito-urinary and respiratory infections (otitis, sinusitis, throat infections, bronchitis and influenza) during the index pregnancy.

Differences between cases and controls in the mean DNA methylation at each CpG site mapping to a DMR identified by the bumphunting procedure were analysed using unpaired t-test. To explore the role of maternal atopy in the observed associations, these analyses were additionally stratified by maternal history of atopic disorders (allergic rhinitis and/or atopic dermatitis).

Analysis of publicly available datasets
To test our main findings in independent samples we identified five datasets from the Gene Expression Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo/). Details on the search of datasets containing epigenome-wide DNA methylation data and phenotypes related to childhood wheezing can be found in the Supporting Information file (Methods, Search of publicly available datasets).

In particular, we used three datasets from the project “Epigenetic profiling of children with respiratory allergy” (GSE110128), which includes children from a Belgian birth cohort with available cord blood samples, and blood and saliva samples collected at age 11 years. DNA methylation from cord blood mononuclear cells (CBMCs), peripheral blood mononuclear cells (PBMCs) and saliva was measured using the Infinium HumanMethylation450 BeadChip array. This project includes processed DNA methylation data from 485,512 CpG sites for 233 samples: 90 cord blood samples (30 respiratory allergy cases and 60 controls), 90 blood samples (29 respiratory allergy cases and 61 controls) and 53 saliva samples (33 respiratory allergy cases and 20 controls). Respiratory allergy was assessed when children were 10 years old and was defined as IgE sensitization to a mix of airborne allergens and self-report or doctor’s diagnosis of at least one of the following: asthma, hay fever, other types of rhinitis, wheezing, or runny nose in the past year and ever.

The remaining two datasets (GSE40576 and GSE65163) include partially overlapping samples of African American or Hispanic with Dominican/Haitian background children from the Inner-City Asthma Consortium (USA). Atopic asthma was defined as persistent physician-diagnosed asthma with altered lung function parameters and positive skin prick test to at least one of a panel of indoor aeroallergens. The GSE40576 dataset includes epigenome-wide DNA methylation measured in PBMCs from 6-12 years old children with atopic asthma (N=97) and healthy controls (N=97). The GSE65163 dataset involves children with atopic asthma (N=36) and healthy controls (N=36) aged 9-12 years and epigenome-wide DNA methylation measured in nasal epithelial cells. Both studies used Infinium HumanMethylation450 BeadChip array to measure DNA methylation. We selected only probes located within the DMR identified in our study, calculated the differences in the mean DNA methylation between cases and controls (delta beta [Δbeta]), and formally tested them using the unpaired t-test. We report one-sided p-values because the alternative hypotheses were determined by the findings from the NINFEA sample. Given the public nature of the datasets, we were not able to perform data quality checks and to correct for cell types, technical covariates and other potential confounders.

Results
Epigenome-wide DNA methylation analysis of early childhood wheezing
Descriptive statistics of the study population are shown in Table 1. Maternal age, educational level, nationality, and smoking after delivery were balanced between cases and controls. Children with wheezing were more likely to be born to mothers with a history of atopic disorders (p=0.09), to have siblings and to have attended day-care compared with controls (both p-values=0.02). Median age at saliva sampling was 10.3 months (interquartile range [IQR] 9.4-11.8 months). In an exploratory epigenome-wide association analysis 25,042 (5.9%) probes were associated with childhood wheezing at the conventional p-value<0.05, but none remained associated after adjustment for multiple comparisons (Bonferroni p-value<1.19e-07 and Benjamini-Hochberg FDR-corrected p-value<0.05). The Manhattan plot of the EWAS results is shown in Figure S1. Of the four DMRs identified by the bumphunting procedure (Table S1) only one region was associated with wheezing with a FWER<0.05 (Table 2). This DMR remained associated with childhood wheezing also after adjustment for maternal history of atopy, maternal depression and anxiety and maternal infections during pregnancy (data not shown).

The identified DMR consists of ten probes located on the chromosome 1 and maps to the promoter region of the PM20D1 gene. All 10 probes were hypermethylated in cases compared with controls, with seven probes having Δbeta from 4.3% to 9.6% (all p-values<0.05, Table 3, first column). The largest differences between cases and controls were identified in the PM20D1 promoter region and in the region of the first exon.
When we stratified analyses on single CpG sites by maternal atopic disorders (Table 3) DNA methylation differences between cases and controls at 7 CpG sites located within the PM20D1 promoter region and the region of the first exon were particularly increased in children born to atopic mothers, with ∆beta ranging from 10% to 20%. The same differences were diluted, but still followed similar pattern, in children of non-atopic mothers.

Analysis of the publicly available datasets

The difference in the mean DNA methylation between cases and controls in 10 probes located within the PM20D1 calculated in the NINFEA sample and in the five public datasets are reported in Figure 1 and Table 4. The PM20D1 probes are ordered according to their base pair position. The seven most strongly associated probes in the NINFEA data were consistently associated with respiratory allergy in 11-year old children when DNA methylation was measured in CBMCs and PBMCs (CBMCs: ∆beta 8.4%-11.7%; PBMCs: ∆beta 10.4%-13.6%; all one-sided p-values<0.05). An analogous direction of the associations, though lower in magnitude, was observed for DNA methylation measured in saliva of 11-year old children. It should be noted that the sample size of the saliva public dataset was small (half of the other two public datasets from the same project) limiting the power of this analysis.

Only two of the 10 probes from the PM20D1 DMR were available in the nasal epithelia dataset of persistent atopic asthma in African-American 9-12 years old children, where the associations were even stronger (Abeta 10%-11%, both one-sided p-values<0.005). Despite the strong associations observed in nasal samples, the differences in PBMCs of children from the same study were much smaller, although still in the same direction.

The three probes that had ∆beta below 1% (and a p-value>0.05) in the NINFEA sample had the greatest distance from the transcriptional start site and the lowest difference in the mean DNA methylation between cases and controls also in all public datasets (Tables 3 and 4).

As GSE40576 PBMCs dataset was accompanied with paired gene expression data (GSE40732) we further examined whether differentially methylated sites impact PM20D1 expression in healthy children (Supporting Information file, Results, Correlation of differentially methylated sites with expression of PM20D1). Although the PM20D1 expression level was not associated with persistent atopic asthma in this dataset (p-value=0.382), there was a negative relationship between DNA methylation in all but one CpG site located within the DMR and PM20D1 expression, with Spearman’s rho ranging from -0.014 to -0.126 (all p-values>0.05, Supporting Information file, Figure S2).

Discussion

We assessed early life saliva genome-wide patterns of DNA methylation related to wheezing between 6 and 18 months of age, and identified one DMR related to early childhood wheezing located in the promoter-regulatory region of PM20D1 gene. The observed associations were particularly strong in children born to atopic mothers. Using a public dataset we also found that DNA methylation of this region, measured at 10 corresponding probes in children’s blood and cord blood, was higher in respiratory allergy cases compared with controls, and that the same pattern of the association, although lower in magnitude, was present when methylation was measured in saliva samples of a subset of the same children. Another public dataset confirmed the observed associations in nasal epithelium from 9-12 years old children with atopic asthma, while the associations were weaker in PBMCs from a partially overlapping sample from the same study.

Our study is based on DNA methylation measured in early infancy, an approach that differs from most of the previous studies that measured methylation in cord blood or later in childhood. Our exploratory epigenome-wide single site analysis showed no single CpG site associated with early wheezing, which is consistent with the findings from the MeDALL consortium, in which 14 CpG sites identified in the discovery study were replicated in peripheral blood from children with school-age asthma, while none of the CpG sites was replicated in analyses focused on early life, where DNA methylation was measured in cord blood. On the other hand, CpG sites and DMRs identified in cord blood of children with school-age and adolescent asthma from the PACE consortium do not include PM20D1, which may reflect more heterogeneous outcome definition in the PACE consortium, which is not strictly related to atopy. Our and the results from the PACE and MeDALL studies suggest that early life
regional, rather than single site, DNA methylation differences are more likely to be associated with childhood atopic and asthmatic phenotypes. These findings also suggest that epigenetic markers for wheezing and asthma tend to develop later in childhood as a consequence of adverse postnatal exposures, or the disease itself, whose effects are not present at birth and in early infancy. The sample size of our study limited the possibility to detect small-magnitude effect sizes that can have functional relevance for childhood and later adulthood health. In fact, the magnitude of the associations for wheezing- and asthma-candidate CpGs identified in several previous EWAS was also small. As the power of our exploratory EWAS was relatively low, we used a more powerful approach that allowed us to identify a wheezing-related differentially methylated region located in *PM20D1* gene. This gene codes Peptidase M20 Domain Containing 1 enzyme that regulates production of N-fatty-acyl amino acids, which are a large family of more than 70 endogenous signalling molecules involved in pain and inflammation regulation, and their metabolites are important mediators of chronic airway inflammation in asthma. Differential DNA methylation patterns at this gene have been previously associated with adult respiratory allergy and maternal asthma. In the study of Langie et al., located in the promoter region of *PM20D1* was hypermethylated in adult individuals with respiratory allergy compared with controls, with similar differential methylation profiles in PBMCs and saliva. Furthermore, hypomethylation of *PM20D1* in blood from 12-month old children was associated with maternal asthma and asthma medication use, maternal atopic status and serum IgE level. In the NINFEA study, on the contrary, hypermethylation of *PM20D1* related to wheezing was much stronger in children born to atopic compared with non-atopic mothers. Although apparently contrasting, findings by Gunawardhana et al. and our own findings both indicate that maternal atopy likely modify offspring atopic phenotypes through alterations in *PM20D1* DNA methylation. In our analyses we accounted for the most important determinants of childhood wheezing, such as maternal age, smoking, child’s siblings and day-care attendance. In particular, the presence of older siblings and day-care attendance, the proxies of early childhood respiratory tract infections and microbial exposure in general, were strongly positively associated with wheezing in our sample, but did not confound the observed association. We acknowledge that we did not perform a “real” replication analysis with a well-planned replication group, and this results in important limitations. First, the phenotypes of the public datasets were different from the one analysed in our sample. Respiratory allergy in three public datasets covers several atopic conditions related to sensitization to airborne allergens, including asthma and wheezing at 10 years of age, while astopic asthma in two other datasets includes persistent asthma with impaired lung function and allergic sensitization. Although our phenotype, namely wheezing in early childhood, is a heterogeneous condition, often related to a relative narrowing of the airways during an acute viral infection, it strongly predicts later asthma development. As all phenotypes in the public datasets have an atopic characterization together with data on respiratory conditions, including wheezing and asthma, we considered them as good candidates for replication of DNA methylation patterns related to wheezing in early childhood. This is further supported by the fact that atopic phenotypes, especially respiratory allergy and atopic asthma/wheezeing, share multiple environmental and genetic risk factors, as well as immunological features. Second, the age of the outcome assessment in our study was different compared with the public datasets (18 months vs. 6-12 years). However, identification of wheezing-related epigenetic markers in early childhood, especially if they overlap with markers of later asthma or respiratory allergy, would allow identification of high-risk children, improve diagnostic and therapeutic approaches, and would contribute to the understanding of the involvement of epigenetics in asthma aetiology. Albeit different traits analysed, the pattern of the association observed in Figure 1 suggests that DNA methylation differences related to preschool wheezing and school-age respiratory allergy and atopic asthma is largely overlapping, which is not likely to be by chance. In fact, consistently increased DNA methylation within the *PM20D1* region was observed in cases compared with controls at different ages (at birth, 10 months in the NINFEA study, and 6-12 years in other four public datasets), as well as in different biological materials analysed (CBMCs, saliva, nasal epithelium and PBMCs). Interestingly, very similar DNA methylation differences related to childhood respiratory allergy were observed between cord blood and blood at 11 years of age in the Belgian
study, suggesting the stability of DNA methylation patterns after birth. Although it has been shown that DNA methylation is influenced also by postnatal environmental exposures, such as early microbial exposures (e.g., DNA methylation of several asthma-candidate genes was strongly influenced by early farming exposure), our findings indicate that this is not a general rule. DNA methylation differences in \textit{PM20D1} related to atopic respiratory phenotypes seem to be determined already at birth and stable over time, suggesting a rather weak impact of postnatal exposures.

One might question why \textit{PM20D1} was not among the top genes identified by previous studies which public datasets we used to replicate our findings.\textsuperscript{19,20,31} However, this is not surprising, as we based our analyses of public datasets on a candidate gene approach compared with the epigenome-wide approach with multiple comparison adjustments reported by previous studies.\textsuperscript{19,20,31} On the other hand, it should be also noted that despite the smaller sample size, the study by Langie et al.\textsuperscript{31} and by Yang et al.\textsuperscript{20} identified many more DMRs compared with our study, and that these DMRs do not overlap with the one DMR identified in our study. One possible explanation could be that the methylation-outcome associations were explored at older ages in the previous two studies which public data was used in our study;\textsuperscript{20,31} this enhanced the possibility to identify a larger number of DMRs, which are also more likely to be a result either of the disease itself or of the accumulating environmental exposures in the first 12 years of life.

One of the limitations of our study is the fact that the time-sequence between DNA methylation measurement and wheezing cannot be clearly established as the period of saliva sample collection (median age 10.3 months) partially overlaps with the period of wheezing assessment (6-18 months). Although the \textit{PM20D1} DMR could also be a consequence of wheezing disorders or postnatal environmental influences, similar pattern of association observed in public cord blood dataset speaks against reverse causation and supports the role of prenatal factors.

Findings from previous studies suggest that the associations observed between DNA methylation and asthma are largely driven by eosinophils\textsuperscript{22,23} that are known to be involved in airway inflammation present in T-helper-2-type asthmatic phenotypes.\textsuperscript{38} However, we used a quite robust method for cell composition adjustment and we believe that the differences observed in \textit{PM20D1} are not likely to be driven by eosinophil count. This is further supported by the findings from the publicly available datasets in which the associations were observed in CBMCs and PBMCs that do not contain eosinophils.

The type of tissue used for DNA methylation measurements is the most innovative element of our study. In the NINFEA study infant samples were collected using saliva sponges at approximately 10 months of age. This non-invasive method of genomic DNA collection is becoming an alternative to the blood DNA collection in large-scale studies, especially if performed on infants and young children. However, there are two aspects that need to be considered when using saliva as a material for epigenetic studies. First, saliva has a heterogeneous cell composition that, in addition to leukocytes, contains a large proportion of epithelial cells that might influence DNA methylation measurements. So far, saliva cell type composition is poorly characterized, and several reference-free methods have been developed to correct for cell type heterogeneity in EWAS.\textsuperscript{28,29} Using simulated scenarios, a study of McGregor et al.\textsuperscript{29} found that surrogate variable analysis had the best performance; thus we used this method to account for cell type composition, batch effects and technical residual confounding. We, therefore, believe that the association observed in our study is not driven by differential cell type composition.

Second, blood and peripheral material, such as saliva, buccal or nasal epithelium, may not be representative of DNA methylation status at central organs involved in a disease pathophysiology. However, various studies identified asthma- and wheezing-related epigenetic marks in several tissues, including nasal and buccal epithelium, whole peripheral blood, cord blood, as well as in mononuclear cells from cord and peripheral blood.\textsuperscript{17,24,36} While blood may be valuable for studying common immunologic processes, nasal and saliva epithelium, being probably closer to the methylation status of the bronchial mucosa than blood or cord blood DNA methylation, are likely better surrogate tissues for studies focused on local inflammation and environmental influences in asthma. These two tissues are also easily accessible and appear to reflect pathological changes in the airways during asthma development.\textsuperscript{26}

In conclusion, we have shown that higher DNA methylation in the promoter-regulatory region of \textit{PM20D1} from infant saliva was associated with the occurrence of early childhood wheezing, especially in children of atopic mothers. Directionally consistent epigenetic alteration observed in cord blood of children with respiratory allergy suggests that this modification might operate from birth, while the confirmation in blood and nasal epithelia of
school-aged children indicates possibly long-term changes. The PM20D1 promoter region was previously implicated in adult respiratory allergy, suggesting its potential role in aetiology of atopic phenotypes, including asthma.

Acknowledgements
The authors are grateful to all the participants of the NINFEA birth cohort.

References
2. Godfrey KM, Lillycrop KA, Burdge GC, Gluckman PD, Hanson MA. Epigenetic mechanisms and the mismatch concept of the developmental origins of health and disease. Pediatr Res. 2007;61:5R-10R.


Table 1. Characteristics of the study population

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Cases</th>
<th>Controls</th>
<th>p-value§</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number</td>
<td>68 (50.0)</td>
<td>68 (50.0)</td>
<td>-</td>
</tr>
<tr>
<td>Maternal age (years)</td>
<td>35.3 (3.8)</td>
<td>34.1 (4.4)</td>
<td>0.10</td>
</tr>
<tr>
<td>Highly educated mothers¶</td>
<td>47 (70.2)</td>
<td>51 (75.0)</td>
<td>0.53</td>
</tr>
<tr>
<td>Mother born outside Italy</td>
<td>3 (4.4)</td>
<td>3 (4.4)</td>
<td>1.00</td>
</tr>
<tr>
<td>Maternal atopic dermatitis and/or allergic rhinitis</td>
<td>21 (31.8)</td>
<td>13 (19.1)</td>
<td>0.09</td>
</tr>
<tr>
<td>Maternal depression and/or anxiety</td>
<td>9 (13.6)</td>
<td>10 (14.7)</td>
<td>0.86</td>
</tr>
<tr>
<td>Genito-urinary infections during pregnancy</td>
<td>10 (15.6)</td>
<td>19 (28.4)</td>
<td>0.08</td>
</tr>
<tr>
<td>Respiratory infections during pregnancy††</td>
<td>22 (34.4)</td>
<td>18 (26.9)</td>
<td>0.35</td>
</tr>
<tr>
<td>≥1 sibling</td>
<td>27 (40.9)</td>
<td>15 (22.4)</td>
<td>0.02</td>
</tr>
<tr>
<td>Child's exposure to passive smoking</td>
<td>7 (10.3)</td>
<td>5 (7.4)</td>
<td>0.55</td>
</tr>
<tr>
<td>Day-care attendance</td>
<td>45 (66.2)</td>
<td>31 (45.6)</td>
<td>0.02</td>
</tr>
<tr>
<td>Child’s eczema 0-18 months</td>
<td>10 (14.7)</td>
<td>13 (19.1)</td>
<td>0.49</td>
</tr>
</tbody>
</table>

Matching variables

<table>
<thead>
<tr>
<th>Sex</th>
<th>Cases</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>38 (55.9)</td>
<td>38 (55.9)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Season of saliva sampling</th>
<th>Cases</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autumn or winter</td>
<td>32 (47.1)</td>
<td>32 (47.1)</td>
</tr>
<tr>
<td>Age at saliva sampling (months)‡‡</td>
<td>10.3 (9.3-11.7)</td>
<td>10.4 (9.4-12.0)</td>
</tr>
</tbody>
</table>

Table 2. Differentially methylated region (DMR) associated with early childhood wheezing

<table>
<thead>
<tr>
<th>Cluster number</th>
<th>Chromosome</th>
<th>Start Position</th>
<th>End Position</th>
<th>Delta β†</th>
<th>Number of probes</th>
<th>p-value</th>
<th>FWER‡</th>
<th>Nearest gene§</th>
</tr>
</thead>
<tbody>
<tr>
<td>12362</td>
<td>1</td>
<td>205818484</td>
<td>205819609</td>
<td>0.077</td>
<td>10</td>
<td>0.006</td>
<td>0.028</td>
<td>PM20D1</td>
</tr>
</tbody>
</table>

† The average difference in DNA methylation between cases and controls
‡ Family-wise error rate from 1000 bootstraps
§ Genome coordinates are given with respect to hg19 genome assembly
Table 3. Associations of DNA methylation in 10 probes, located within the differentially methylated region in *PM20D1* with childhood wheezing, stratified by maternal history of atopic disorders, ordered by the base pair position.

<table>
<thead>
<tr>
<th>Probe</th>
<th>Base pair position†</th>
<th>Genic location‡</th>
<th>NINFEA (N=136)</th>
<th>Maternal atopic disorders††</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Delta β§ (%)</td>
<td>p-value¶</td>
<td>Delta β§ (%)</td>
</tr>
<tr>
<td>N=100 (No)</td>
<td></td>
<td></td>
<td></td>
<td>N=34 (Yes)</td>
</tr>
<tr>
<td>cg07157834</td>
<td>205819609</td>
<td>0.77</td>
<td>0.587</td>
<td>0.99</td>
</tr>
<tr>
<td>cg24503407</td>
<td>205819492</td>
<td>4.25</td>
<td>0.047</td>
<td>2.95</td>
</tr>
<tr>
<td>cg07167872</td>
<td>205819463</td>
<td>5.19</td>
<td>0.018</td>
<td>3.52</td>
</tr>
<tr>
<td>cg11965913</td>
<td>205819406</td>
<td>8.93</td>
<td>0.009</td>
<td>5.73</td>
</tr>
<tr>
<td>cg14893161</td>
<td>205819251</td>
<td>9.15</td>
<td>0.009</td>
<td>5.68</td>
</tr>
<tr>
<td>cg14159672</td>
<td>205819179</td>
<td>9.58</td>
<td>0.009</td>
<td>6.61</td>
</tr>
<tr>
<td>cg26354017</td>
<td>205819088</td>
<td>9.14</td>
<td>0.004</td>
<td>5.38</td>
</tr>
<tr>
<td>cg17178900</td>
<td>205818956</td>
<td>6.36</td>
<td>0.006</td>
<td>4.06</td>
</tr>
<tr>
<td>cg06815965</td>
<td>205818668</td>
<td>0.40</td>
<td>0.576</td>
<td>0.54</td>
</tr>
<tr>
<td>cg03461704</td>
<td>205818484</td>
<td>0.15</td>
<td>0.809</td>
<td>-0.06</td>
</tr>
</tbody>
</table>

† Genome coordinates are given with respect to hg19 genome assembly
‡ According to UCSC reference gene information
§ The difference in the mean DNA methylation between cases and controls (%)
¶ P-values based on a two-sided Student’s t-test for the difference in the mean DNA methylation between cases and controls.
†† Maternal history of allergic rhinitis and/or atopic dermatitis

Table 4. Associations of DNA methylation in 10 probes, located within the differentially methylated region in *PM20D1*, with wheezing in the NINFEA sample and with childhood respiratory allergy/atopic asthma, in the five publicly available datasets, ordered by the base pair position.

<table>
<thead>
<tr>
<th>Probe</th>
<th>NINFEA (wheezing)</th>
<th>GSE110128 (respiratory allergy)</th>
<th>GSE40576 (atopic asthma)</th>
<th>GSE65163 (atopic asthma)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Delta β† (%)</td>
<td>p-value</td>
<td>Delta β† (%)</td>
<td>p-value</td>
</tr>
<tr>
<td>6-18 months</td>
<td>Saliva (N=136)</td>
<td></td>
<td>Saliva (N=53)</td>
<td>Blood§ (N=90)</td>
</tr>
<tr>
<td>11 years</td>
<td>0.77</td>
<td>0.58</td>
<td>0.761</td>
<td>6.69</td>
</tr>
<tr>
<td>6-12 years</td>
<td>4.25</td>
<td>0.04</td>
<td>0.116</td>
<td>12.06</td>
</tr>
</tbody>
</table>

† Genome coordinates are given with respect to hg19 genome assembly
‡ According to UCSC reference gene information
§ P-values based on a two-sided Student’s t-test for the difference in the mean DNA methylation between cases and controls.
†† Maternal history of allergic rhinitis and/or atopic dermatitis
<table>
<thead>
<tr>
<th>Feature</th>
<th>Base Mean</th>
<th>P-value</th>
<th>Mean</th>
<th>P-value</th>
<th>Mean</th>
<th>P-value</th>
<th>Mean</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>cg07167872</td>
<td>5.19</td>
<td>0.01</td>
<td>9.19</td>
<td>0.066</td>
<td>12.17</td>
<td>0.00</td>
<td>11.66</td>
<td>0.006</td>
</tr>
<tr>
<td>cg11965913</td>
<td>8.93</td>
<td>0.00</td>
<td>4.80</td>
<td>0.264</td>
<td>13.59</td>
<td>0.00</td>
<td>10.43</td>
<td>0.027</td>
</tr>
<tr>
<td>cg14893161</td>
<td>9.15</td>
<td>0.00</td>
<td>4.16</td>
<td>0.276</td>
<td>10.44</td>
<td>0.02</td>
<td>8.89</td>
<td>0.037</td>
</tr>
<tr>
<td>cg14159672</td>
<td>9.58</td>
<td>0.00</td>
<td>5.55</td>
<td>0.215</td>
<td>12.12</td>
<td>0.01</td>
<td>10.42</td>
<td>0.021</td>
</tr>
<tr>
<td>cg263540</td>
<td>9.1</td>
<td>0.004</td>
<td>5.61</td>
<td>0.21</td>
<td>11.89</td>
<td>0.012</td>
<td>10.71</td>
<td>0.02</td>
</tr>
<tr>
<td>cg171789</td>
<td>6.3</td>
<td>0.006</td>
<td>7.81</td>
<td>0.13</td>
<td>11.43</td>
<td>0.019</td>
<td>8.39</td>
<td>0.04</td>
</tr>
<tr>
<td>cg06815965</td>
<td>0.40</td>
<td>0.57</td>
<td>-1.18</td>
<td>0.997</td>
<td>0.73</td>
<td>0.01</td>
<td>0.75</td>
<td>0.051</td>
</tr>
<tr>
<td>cg03461704</td>
<td>0.15</td>
<td>0.80</td>
<td>0.15</td>
<td>0.464</td>
<td>0.44</td>
<td>0.36</td>
<td>0.67</td>
<td>0.339</td>
</tr>
</tbody>
</table>

† The difference in the mean DNA methylation between cases and controls (%)
‡ P-values based on a one-sided Student’s t-test for the difference in the mean DNA methylation between cases and controls.
§ Peripheral blood mononuclear cell (PBMC) fraction